Literature DB >> 18183580

Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging.

Azzam A Khankan1, Takamichi Murakami, Hiromitsu Onishi, Masaki Matsushita, Riccardo Iannaccone, Yoshiko Aoki, Takeshi Tono, Tonsok Kim, Masatoshi Hori, Keigo Osuga, Roberto Passariello, Hironobu Nakamura.   

Abstract

PURPOSE: To determine the usefulness of nonenhanced T1-weighted spoiled gradient-recalled acquisition in the steady-state (SPGR) MRI in the early assessment of the efficacy of radio frequency (RF) therapy for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: A total of 23 patients with 28 HCC nodules treated with percutaneous RF ablation underwent nonenhanced MRI within two days after the RF procedure and contrast-enhanced computed tomography (CT) one week after. MR assessment of ablation efficacy according to the concentric zonal pattern on T1-weighted SPGR imaging was compared with the one-week CT and presence of local recurrence by means of follow-up study for 12 months or more.
RESULTS: In 18 of 28 ablated nodules, SPGR images revealed a central hyperintense zone covering the entire tumor, CT showed a nonenhanced area covering the entire tumor, and no local recurrence was demonstrated in the follow-up studies. In nine of 28 nodules, the central hyperintense zone did not cover the entire tumor; and local recurrence was demonstrated in three nodules. In the remaining one nodule, no signal change was seen in the treated area on SPGR images and CT showed the presence of residual viable tumor.
CONCLUSION: Nonenhanced T1-weighted MRI was considered useful for early assessment of the efficacy of RF therapy for HCC.

Entities:  

Mesh:

Year:  2008        PMID: 18183580     DOI: 10.1002/jmri.21050

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  6 in total

Review 1.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 2.  Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-04-08       Impact factor: 11.740

3.  Local curative effect of MRI-guided radiofrequency ablation on small hepatocellular carcinoma.

Authors:  Zheng-Yu Lin; Qian-Qian Song; Jin Chen; Ren-Jun Wan; Hui Zheng; Zhong-Wu Chen; Yi-Ping Chen; Wang-Chun Hua
Journal:  Tumour Biol       Date:  2014-12-14

Review 4.  MRI of hepatocellular carcinoma: an update of current practices.

Authors:  Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

5.  Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.

Authors:  Vincenza Granata; Elisabetta de Lutio di Castelguidone; Roberta Fusco; Orlando Catalano; Mauro Piccirillo; Raffaele Palaia; Francesco Izzo; Adolfo D'Errico Gallipoli; Antonella Petrillo
Journal:  Radiol Med       Date:  2015-09-07       Impact factor: 3.469

Review 6.  MRI assessment of hepatocellular carcinoma after locoregional therapy.

Authors:  Rasha S Hussein; Wahid Tantawy; Yasser A Abbas
Journal:  Insights Imaging       Date:  2019-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.